<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DIFICID- fidaxomicin tablet, film coated </strong><br>Cubist Pharmaceuticals U.S.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use DIFICID<span class="Sup">®</span> safely and effectively. See full prescribing information for DIFICID.<br><br>DIFICID (fidaxomicin) tablets, for oral use<br>Initial U.S. approval: 2011<br><br>To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by <span class="Italics">Clostridium difficile</span>.<br>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">DIFICID is a macrolide antibacterial drug indicated in adults (≥18 years of age) for treatment of <span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (<a href="#splSection1">1.1</a>). </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">One 200 mg tablet orally twice daily for 10 days with or without food (<a href="#splSectionPLRDosageAdministration">2</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Film-coated tablets: 200 mg (<a href="#splSectionPLRDosageFormsStrength">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to fidaxomicin. (<a href="#splSectionPLRContraindications">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>DIFICID should not be used for systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. (<a href="#splSection13">5.1</a>)</li>
<li>Acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>) have been reported. In the event of a severe reaction, discontinue DIFICID. (<a href="#splSection14">5.2</a>)</li>
<li>Development of drug-resistant bacteria: Only use DIFICID for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> proven or strongly suspected to be caused by <span class="Italics">C. difficile</span>. (<a href="#splSection15">5.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (11%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (7%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (6%), <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> (4%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (2%), and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (2%) (<a href="#splSectionPLRAdverseReactions">6</a>). </p>
<p class="Highlighta"><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Cubist Pharmaceuticals at 1-877-CUBIST-6 (1-877-282-4786) or FDA at (1-800-FDA-1088) or </span><span class="Bold Italics">www.fda.gov/medwatch</span>. </p>
</div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Pediatrics: The safety and effectiveness of DIFICID has not been studied in patients &lt;18 years of age (<a href="#splSectionPLRPediatric">8.4</a>). </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 5/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="Italics">Clostridium difficile</span>-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Not for Systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Development of Drug-Resistant Bacteria</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Cyclosporine</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Administration with Food</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Antibacterial Resistance</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionPLRIndicationsUsage"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID<span class="Sup">®</span> and other antibacterial drugs, DIFICID should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by <span class="Italics">Clostridium difficile</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="Italics">Clostridium difficile</span>-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First">DIFICID is a macrolide antibacterial drug indicated in adults (≥18 years of age) for treatment of <span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD).</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionPLRDosageAdministration"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose is one 200 mg DIFICID tablet orally twice daily for 10 days with or without food.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="splSectionPLRDosageFormsStrength"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">200 mg white to off-white film-coated, oblong tablets; each tablet is debossed with "FDX" on one side and "200" on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionPLRContraindications"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to fidaxomicin.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="splSectionPLRWarnings"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection13"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Not for Systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Since there is minimal systemic absorption of fidaxomicin, DIFICID is not effective for treatment of systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection14"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> of the mouth, throat, and face have been reported with fidaxomicin. If a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> occurs, DIFICID<span class="Sup">®</span> should be discontinued and appropriate therapy should be instituted.</p>
<p>Some patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> also reported a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to other macrolides. Physicians prescribing DIFICID to patients with a known macrolide <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> should be aware of the possibility of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection15"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Development of Drug-Resistant Bacteria</h2>
<p class="First">Prescribing DIFICID in the absence of a proven or strongly suspected <span class="Italics">C. difficile</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionPLRAdverseReactions"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection11"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of any other drug and may not reflect the rates observed in practice.</p>
<p>The safety of DIFICID 200 mg tablets taken twice a day for 10 days was evaluated in 564 patients with CDAD in two active-comparator controlled trials with 86.7% of patients receiving a full course of treatment.</p>
<p>Thirty-three patients receiving DIFICID (5.9%) withdrew from trials as a result of adverse reactions (AR). The types of AR resulting in withdrawal from the study varied considerably. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> was the primary adverse reaction leading to discontinuation of dosing; this occurred at an incidence of 0.5% in both the fidaxomicin and vancomycin patients in Phase 3 studies.</p>
<table width="80%">
<caption><span>Table 1. Selected Adverse Reactions with an Incidence of ≥2% Reported in DIFICID Patients in Controlled Trials</span></caption>
<col align="left" width="50%">
<col align="center" width="25%">
<col align="center" width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule" align="left"></td>
<td class="Botrule" align="center">
<span class="Bold">DIFICID</span><br><span class="Bold">(N=564)</span>
</td>
<td class="Botrule Rrule" align="center">
<span class="Bold">Vancomycin</span><br><span class="Bold">(N=583)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">
<span class="Bold">System Organ Class</span><br><span class="Bold">    Preferred Term</span>
</td>
<td class="Botrule" align="center"><span class="Bold">n (%)</span></td>
<td class="Botrule Rrule" align="center"><span class="Bold">n (%)</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3">Blood and Lymphatic System Disorders</td></tr>
<tr>
<td class="Botrule Lrule" align="left">    <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Botrule" align="center">14 (2%)</td>
<td class="Botrule Rrule" align="center">12 (2%)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">    <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Botrule" align="center">14 (2%)</td>
<td class="Botrule Rrule" align="center">6 (1%)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></td></tr>
<tr>
<td class="Botrule Lrule" align="left">    <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule" align="center">62 (11%)</td>
<td class="Botrule Rrule" align="center">66 (11%)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">    <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule" align="center">41 (7%)</td>
<td class="Botrule Rrule" align="center">37 (6%)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">    <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Botrule" align="center">33 (6%)</td>
<td class="Botrule Rrule" align="center">23 (4%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">    <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal Hemorrhage</span></td>
<td class="Botrule" align="center">20 (4%)</td>
<td class="Botrule Rrule" align="center">12 (2%)</td>
</tr>
</tbody>
</table>
<p>The following adverse reactions were reported in &lt;2% of patients taking DIFICID tablets in controlled trials:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span>  <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="197981" conceptname="Abdominal tenderness">abdominal tenderness</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span></p>
<p><span class="Italics">Investigations:</span>  increased blood alkaline phosphatase, decreased blood <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, increased hepatic enzymes, decreased platelet count</p>
<p><span class="Italics">Metabolism and Nutrition Disorders:</span>  <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span></p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders:</span>  <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug eruption</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection12"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post Marketing Experience</h2>
<p class="First">Adverse reactions reported in the post marketing setting arise from a population of unknown size and are voluntary in nature. As such, reliability in estimating their frequency or in establishing a causal relationship to drug exposure is not always possible.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> (<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>) have been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="splSectionPLRDrugInteract"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Fidaxomicin and its main metabolite, OP-1118, are substrates of the efflux transporter, P-glycoprotein (P-gp), which is expressed in the gastrointestinal tract.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection5"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Cyclosporine</h2>
<p class="First">Cyclosporine is an inhibitor of multiple transporters, including P-gp. When cyclosporine was co-administered with DIFICID, plasma concentrations of fidaxomicin and OP-1118 were significantly increased but remained in the ng/mL range <span class="Italics">[see Clinical Pharmacology (<a href="#splSectionPLRPharmacokinetics">12.3</a>)]</span>. Concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) via P-gp inhibition; however, concomitant P-gp inhibitor use had no attributable effect on safety or treatment outcome of fidaxomicin-treated patients in controlled clinical trials. Based on these results, fidaxomicin may be co-administered with P-gp inhibitors and no dose adjustment is recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="splSectionPLRPopulations"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPLRPregnancy"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category B. Reproduction studies have been performed in rats and rabbits by the intravenous route at doses up to 12.6 and 7 mg/kg, respectively. The plasma exposures (AUC<span class="Sub">0-t</span>) at these doses were approximately 200- and 66-fold that in humans, respectively, and have revealed no evidence of harm to the fetus due to fidaxomicin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPLRNursing"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether fidaxomicin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when DIFICID is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPLRPediatric"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of DIFICID in patients &lt;18 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="splSectionPLRGeriatric"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of patients in controlled trials of DIFICID<span class="Sup">®</span>, 50% were 65 years of age and over, while 31% were 75 and over. No overall differences in safety or effectiveness of fidaxomicin compared to vancomycin were observed between these subjects and younger subjects.</p>
<p>In controlled trials, elderly patients (≥65 years of age) had higher plasma concentrations of fidaxomicin and its main metabolite, OP-1118, versus non-elderly patients (&lt;65 years of age) <span class="Italics">[see Clinical Pharmacology (<a href="#splSectionPLRPharmacokinetics">12.3</a>)]</span>. However, greater exposures in elderly patients were not considered to be clinically significant. No dose adjustment is recommended for elderly patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="splSectionPLROverdose"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> have been reported in humans. No drug-related adverse effects were seen in dogs dosed with fidaxomicin tablets at 9600 mg/day (over 100 times the human dose, scaled by weight) for 3 months.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionPLRDescription"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">DIFICID (fidaxomicin) is a macrolide antibacterial drug for oral administration. Its CAS chemical name is Oxacyclooctadeca-3,5,9,13,15-pentaen-2-one, 3-[[[6-deoxy-4-<span class="Italics">O</span>-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-<span class="Italics">O</span>-methyl-β-D-mannopyranosyl]oxy]methyl]-12-[[6-deoxy-5-<span class="Italics">C</span>-methyl-4-<span class="Italics">O</span>-(2-methyl-1-oxopropyl)-β-D-<span class="Italics">lyxo</span>-hexopyranosyl]oxy]-11-ethyl-8-hydroxy-18-[(1<span class="Italics">R</span>)-1-hydroxyethyl]-9,13,15-trimethyl-, (3<span class="Italics">E</span>,5<span class="Italics">E</span>,8<span class="Italics">S</span>,9<span class="Italics">E</span>,11<span class="Italics">S</span>,12<span class="Italics">R</span>,13<span class="Italics">E</span>,15<span class="Italics">E</span>,18<span class="Italics">S</span>)-. The structural formula of fidaxomicin is shown in Figure 1.</p>
<p><img alt="dificid-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd966338-c820-4270-b704-09ef75fa3ceb&amp;name=dificid-01.jpg"></p>
<table class="Noautorules" width="80%">
<col align="center" valign="top" width="100%">
<tbody class="Headless"><tr><td align="center"><span class="Bold">Figure 1. Structural Formula of Fidaxomicin</span></td></tr></tbody>
</table>
<p>DIFICID tablets (200 mg) are film-coated and contain the following inactive ingredients: microcrystalline cellulose, pregelatinized starch, hydroxypropyl cellulose, butylated hydroxytoluene, sodium starch glycolate, magnesium stearate, polyvinyl alcohol, titanium dioxide, talc, polyethylene glycol, and lecithin (soy).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionPLRClinicalPharm"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="splSectionPLRMechAction"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Fidaxomicin is an antibacterial drug <span class="Italics">[see Microbiology (<a href="#splSection6">12.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="splSectionPLRPharmacodynamics"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Fidaxomicin acts locally in the gastrointestinal tract on <span class="Italics">C. difficile</span>. In a dose-ranging trial (N=48) of fidaxomicin using 50 mg, 100 mg, and 200 mg twice daily for 10 days, a dose-response relationship was observed for efficacy.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="splSectionPLRPharmacokinetics"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetic parameters of fidaxomicin and its main metabolite OP-1118 following a single dose of 200 mg in healthy adult males (N=14) are summarized in Table 2.</p>
<table width="80%">
<caption><span>Table 2. Mean (± Standard Deviation) Pharmacokinetic Parameters of Fidaxomicin 200 mg in Healthy Adult Males</span></caption>
<col align="left" width="32%">
<col align="center" width="17%">
<col align="center" width="17%">
<col align="center" width="17%">
<col align="center" width="17%">
<tfoot><tr class="First Last"><td align="left" colspan="5">* T<span class="Sub">max</span>, reported as median (range)<br>   C<span class="Sub">max</span>, maximum observed concentration; T<span class="Sub">max</span>, time to maximum observed concentration; AUC<span class="Sub">0-t</span>, area under the concentration-time curve from time 0 to the last measured concentration; AUC<span class="Sub">0-∞</span>, area under the concentration-time curve from time 0 to infinity; t<span class="Sub">1/2</span>, elimination half-life</td></tr></tfoot>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Lrule Rrule" align="left" rowspan="2"><span class="Bold">Parameter</span></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><span class="Bold">Fidaxomicin</span></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><span class="Bold">OP-1118</span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule" align="center"><span class="Bold">N</span></td>
<td class="Botrule Rrule" align="center"><span class="Bold">Value</span></td>
<td class="Botrule Lrule" align="center"><span class="Bold">N</span></td>
<td class="Botrule Rrule" align="center"><span class="Bold">Value</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">C<span class="Sub">max</span> (ng/mL)</td>
<td class="Botrule Lrule" align="center">14</td>
<td class="Botrule Rrule" align="center">5.20 ± 2.81</td>
<td class="Botrule Lrule" align="center">14</td>
<td class="Botrule Rrule" align="center">12.0 ± 6.06</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">T<span class="Sub">max</span> (h)*</td>
<td class="Botrule Lrule" align="center">14</td>
<td class="Botrule Rrule" align="center">2.00 (1.00-5.00)</td>
<td class="Botrule Lrule" align="center">14</td>
<td class="Botrule Rrule" align="center">1.02 (1.00-5.00)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">AUC<span class="Sub">0-t</span> (ng-h/mL)</td>
<td class="Botrule Lrule" align="center">14</td>
<td class="Botrule Rrule" align="center">48.3 ± 18.4</td>
<td class="Botrule Lrule" align="center">14</td>
<td class="Botrule Rrule" align="center">103 ± 39.4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">AUC<span class="Sub">0-∞</span> (ng-h/mL)</td>
<td class="Botrule Lrule" align="center">9</td>
<td class="Botrule Rrule" align="center">62.9 ± 19.5</td>
<td class="Botrule Lrule" align="center">10</td>
<td class="Botrule Rrule" align="center">118 ± 43.3</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">t<span class="Sub">1/2</span> (h)</td>
<td class="Botrule Lrule" align="center">9</td>
<td class="Botrule Rrule" align="center">11.7 ± 4.80</td>
<td class="Botrule Lrule" align="center">10</td>
<td class="Botrule Rrule" align="center">11.2 ± 3.01</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Absorption</span></p>
<p>Fidaxomicin has minimal systemic absorption following oral administration, with plasma concentrations of fidaxomicin and OP-1118 in the ng/mL range at the therapeutic dose. In fidaxomicin-treated patients from controlled trials, plasma concentrations of fidaxomicin and OP-1118 obtained within the T<span class="Sub">max</span> window (1-5 hours) were approximately 2- to 6-fold higher than C<span class="Sub">max</span> values in healthy adults. Following administration of DIFICID 200 mg twice daily for 10 days, OP-1118 plasma concentrations within the T<span class="Sub">max</span> window were approximately 50%-80% higher than on Day 1, while concentrations of fidaxomicin were similar on Days 1 and 10.</p>
<p>In a food-effect study involving administration of DIFICID to healthy adults (N=28) with a high-fat meal versus under fasting conditions, C<span class="Sub">max</span> of fidaxomicin and OP-1118 decreased by 21.5% and 33.4%, respectively, while AUC<span class="Sub">0-t</span> remained unchanged. This decrease in C<span class="Sub">max</span> is not considered clinically significant, and thus, DIFICID may be administered with or without food.</p>
<p><span class="Bold">Distribution</span></p>
<p>Fidaxomicin is mainly confined to the gastrointestinal tract following oral administration. In selected patients (N=8) treated with DIFICID 200 mg twice daily for 10 days from controlled trials, fecal concentrations of fidaxomicin and OP-1118 obtained within 24 hours of the last dose ranged from 639-2710 μg/g and 213-1210 μg/g, respectively. In contrast, plasma concentrations of fidaxomicin and OP-1118 within the T<span class="Sub">max</span> window (1-5 hours) ranged 2-179 ng/mL and 10-829 ng/mL, respectively.</p>
<p><span class="Bold">Metabolism</span></p>
<p>Fidaxomicin is primarily transformed by hydrolysis at the isobutyryl ester to form its main and microbiologically active metabolite, OP-1118. Metabolism of fidaxomicin and formation of OP-1118 are not dependent on cytochrome P450 (CYP) enzymes.</p>
<p>At the therapeutic dose, OP-1118 was the predominant circulating compound in healthy adults, followed by fidaxomicin.</p>
<p><span class="Bold">Excretion</span></p>
<p>Fidaxomicin is mainly excreted in feces. In one trial of healthy adults (N=11), more than 92% of the dose was recovered in the stool as fidaxomicin and OP-1118 following single doses of 200 mg and 300 mg. In another trial of healthy adults (N=6), 0.59% of the dose was recovered in urine as OP-1118 only following a single dose of 200 mg.</p>
<p><span class="Bold">Specific Populations</span></p>
<p><span class="Bold">Geriatric</span></p>
<p>In controlled trials of patients treated with DIFICID<span class="Sup">®</span> 200 mg twice daily for 10 days, mean and median values of fidaxomicin and OP-1118 plasma concentrations within the T<span class="Sub">max</span> window (1-5 hours) were approximately 2- to 4-fold higher in elderly patients (≥65 years of age) versus non-elderly patients (&lt;65 years of age). Despite greater exposures in elderly patients, fidaxomicin and OP-1118 plasma concentrations remained in the ng/mL range <span class="Italics">[see Use in Specific Populations (<a href="#splSectionPLRGeriatric">8.5</a>)]</span>.</p>
<p><span class="Bold">Gender</span></p>
<p>Plasma concentrations of fidaxomicin and OP-1118 within the T<span class="Sub">max</span> window (1-5 hours) did not vary by gender in patients treated with DIFICID 200 mg twice daily for 10 days from controlled trials. No dose adjustment is recommended based on gender.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>In controlled trials of patients treated with DIFICID 200 mg twice daily for 10 days, plasma concentrations of fidaxomicin and OP-1118 within the T<span class="Sub">max</span> window (1-5 hours) did not vary by severity of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (based on creatinine clearance) between mild (51-79 mL/min), moderate (31-50 mL/min), and severe (≤30 mL/min) categories. No dose adjustment is recommended based on renal function.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>The impact of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of fidaxomicin has not been evaluated. Because fidaxomicin and OP-1118 do not appear to undergo significant hepatic metabolism, elimination of fidaxomicin and OP-1118 is not expected to be significantly affected by <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p><span class="Bold">Drug Interactions</span></p>
<p><span class="Italics">In vivo </span> studies were conducted to evaluate intestinal drug-drug interactions of fidaxomicin as a P-gp substrate, P-gp inhibitor, and inhibitor of major CYP enzymes expressed in the gastrointestinal tract (CYP3A4, CYP2C9, and CYP2C19).</p>
<p>Table 3 summarizes the impact of a co-administered drug (P-gp inhibitor) on the pharmacokinetics of fidaxomicin <span class="Italics">[see Drug Interactions (<a href="#splSection5">7.1</a>)]</span>.</p>
<table width="80%">
<caption><span>Table 3. Pharmacokinetic Parameters of Fidaxomicin and OP-1118 in the Presence of a Co-Administered Drug</span></caption>
<col align="left" width="26%">
<col align="center" width="12%">
<col align="center" width="12%">
<col align="center" width="12%">
<col align="center" width="12%">
<col align="center" width="26%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Cyclosporine was administered 1 hour before fidaxomicin</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>CI - confidence interval</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" rowspan="2"><span class="Bold">Parameter</span></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">
<span class="Bold">Cyclosporine 200 mg + Fidaxomicin 200 mg<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span><br><span class="Bold">(N=14)</span>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">
<span class="Bold">Fidaxomicin 200 mg Alone</span><br><span class="Bold">(N=14)</span>
</td>
<td class="Botrule Lrule Rrule" align="center" rowspan="2">
<span class="Bold">Mean Ratio of Parameters With/Without Co-Administered Drug<br>(90% CI <a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>)</span><br><span class="Bold">No Effect = 1.00</span>
</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule" align="center"><span class="Bold">N</span></td>
<td class="Botrule Rrule" align="center"><span class="Bold">Mean</span></td>
<td class="Botrule Lrule" align="center"><span class="Bold">N</span></td>
<td class="Botrule Rrule" align="center"><span class="Bold">Mean</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Fidaxomicin</td>
<td class="Botrule Lrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Lrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">    C<span class="Sub">max</span> (ng/mL)</td>
<td class="Botrule Lrule" align="center">14</td>
<td class="Botrule Rrule" align="center">19.4</td>
<td class="Botrule Lrule" align="center">14</td>
<td class="Botrule Rrule" align="center">4.67</td>
<td class="Botrule Lrule Rrule" align="center">4.15 (3.23-5.32)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">    AUC<span class="Sub">0-∞</span> (ng-h/mL)</td>
<td class="Botrule Lrule" align="center">8</td>
<td class="Botrule Rrule" align="center">114</td>
<td class="Botrule Lrule" align="center">9</td>
<td class="Botrule Rrule" align="center">59.5</td>
<td class="Botrule Lrule Rrule" align="center">1.92 (1.39-2.64)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">OP-1118</td>
<td class="Botrule Lrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Lrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">    C<span class="Sub">max</span> (ng/mL)</td>
<td class="Botrule Lrule" align="center">14</td>
<td class="Botrule Rrule" align="center">100</td>
<td class="Botrule Lrule" align="center">14</td>
<td class="Botrule Rrule" align="center">10.6</td>
<td class="Botrule Lrule Rrule" align="center">9.51 (6.93-13.05)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">    AUC<span class="Sub">0-∞</span> (ng-h/mL)</td>
<td class="Botrule Lrule" align="center">12</td>
<td class="Botrule Rrule" align="center">438</td>
<td class="Botrule Lrule" align="center">10</td>
<td class="Botrule Rrule" align="center">106</td>
<td class="Botrule Lrule Rrule" align="center">4.11 (3.06-5.53)</td>
</tr>
</tbody>
</table>
<p>Fidaxomicin had no significant impact on the pharmacokinetics of the following co-administered drugs: digoxin (P-gp substrate), midazolam (CYP3A4 substrate), warfarin (CYP2C9 substrate), and omeprazole (CYP2C19 substrate). No dose adjustment is warranted when fidaxomicin is co-administered with substrates of P-gp or CYP enzymes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection6"></a><a name="section-11.4"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Bold">Spectrum of Activity</span></p>
<p>Fidaxomicin is a fermentation product obtained from the Actinomycete <span class="Italics">Dactylosporangium aurantiacum</span>. <span class="Italics">In vitro, </span> fidaxomicin is active primarily against species of clostridia, including <span class="Italics">Clostridium difficile</span>.</p>
<p><span class="Bold">Mechanism of Action</span></p>
<p>Fidaxomicin is bactericidal against <span class="Italics">C. difficile in vitro</span>, inhibiting RNA synthesis by RNA polymerases.</p>
<p><span class="Bold">Mechanism of Decreased Susceptibility to Fidaxomicin</span></p>
<p><span class="Italics">In vitro </span> studies indicate a low frequency of spontaneous resistance to fidaxomicin in <span class="Italics">C. difficile</span> (ranging from &lt;1.4 × 10<span class="Sup">-9</span> to 12.8 × 10<span class="Sup">-9</span>). A specific mutation (Val-ll43-Gly) in the beta subunit of RNA polymerase is associated with reduced susceptibility to fidaxomicin. This mutation was created in the laboratory and seen during clinical trials in a <span class="Italics">C. difficile</span> isolate obtained from a subject treated with DIFICID who had recurrence of CDAD. The <span class="Italics">C. difficile</span> isolate from the treated subject went from a fidaxomicin baseline minimal inhibitory concentration (MIC) of 0.06 μg/mL to 16 μg/mL.</p>
<p><span class="Bold">Cross-Resistance/Synergy/Post-Antibiotic Effect</span></p>
<p>Fidaxomicin demonstrates no <span class="Italics">in vitro</span> cross-resistance with other classes of antibacterial drugs. Fidaxomicin and its main metabolite OP-1118 do not exhibit any antagonistic interaction with other classes of antibacterial drugs. <span class="Italics">In vitro</span> synergistic interactions of fidaxomicin and OP-1118 have been observed <span class="Italics">in vitro</span> with rifampin and rifaximin against <span class="Italics">C. difficile</span> (FIC values ≤0.5). Fidaxomicin demonstrates a post-antibiotic effect vs. <span class="Italics">C. difficile</span> of 6-10 hrs.</p>
<p><span class="Bold">Susceptibility Testing</span></p>
<p>The clinical microbiology laboratory should provide cumulative results of the <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting appropriate antimicrobial drug therapy.</p>
<p><span class="Bold">Dilution Techniques</span></p>
<p>Quantitative anaerobic <span class="Italics">in vitro</span> methods can be used to determine the MIC of fidaxomicin needed to inhibit the growth of the <span class="Italics">C. difficile</span> isolates. The MIC provides an estimate of the susceptibility of <span class="Italics">C. difficile</span> isolate to fidaxomicin. The MIC should be determined using standardized procedures.<span class="Sup">1</span> Standardized methods are based on an agar dilution method or equivalent with standardized inoculum concentrations and standardized concentration of fidaxomicin powder.</p>
<p><span class="Bold">Susceptibility Test Interpretive Criteria</span></p>
<p><span class="Italics">In vitro</span> susceptibility test interpretive criteria for fidaxomicin have not been determined. The relation of the <span class="Italics">in vitro</span> fidaxomicin MIC to clinical efficacy of fidaxomicin against <span class="Italics">C. difficile</span> isolates can be monitored using <span class="Italics">in vitro</span> susceptibility results obtained from standardized anaerobe susceptibility testing methods.</p>
<p><span class="Bold">Quality Control Parameters for Susceptibility Testing</span></p>
<p><span class="Italics">In vitro</span> susceptibility test quality control parameters were developed for fidaxomicin so that laboratories determining the susceptibility of <span class="Italics">C. difficile</span> isolates to fidaxomicin can ascertain whether the susceptibility test is performing correctly. Standardized dilution techniques require the use of laboratory control microorganisms to monitor the technical aspects of the laboratory procedures. Standardized fidaxomicin powder should provide the MIC with the indicated quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> shown in Table 4.</p>
<table width="80%">
<caption><span>Table 4. Acceptable Quality Control Ranges for Fidaxomicin</span></caption>
<col align="center" width="50%">
<col align="center" width="50%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule" align="center"><span class="Bold">Microorganism</span></td>
<td class="Botrule Rrule" align="center"><span class="Bold">MIC Range (μg/mL)</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center">
<span class="Italics">C. difficile</span> (ATCC 700057)</td>
<td class="Botrule Rrule" align="center">0.03-0.25</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="splSectionPLRNonClinical"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPLRPrecautionsCarcinogen"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<p class="First">Long-term carcinogenicity studies have not been conducted to evaluate the carcinogenic potential of fidaxomicin.</p>
<p>Neither fidaxomicin nor OP-1118 was mutagenic in the Ames assay. Fidaxomicin was also negative in the rat micronucleus assay. However, fidaxomicin was clastogenic in Chinese hamster ovary cells.</p>
<p>Fidaxomicin did not affect the fertility of male and female rats at intravenous doses of 6.3 mg/kg. The exposure (AUC<span class="Sub">0-t</span>) was approximately 100 times that in humans.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="splSectionPLRClinicalStudies"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">In two randomized, double-blinded trials, a non-inferiority design was utilized to demonstrate the efficacy of DIFICID<span class="Sup">®</span> (200 mg twice daily for 10 days) compared to vancomycin (125 mg four times daily for 10 days) in adults with <span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD).</p>
<p>Enrolled patients were 18 years of age or older, and received no more than 24 hours of pretreatment with vancomycin or metronidazole. CDAD was defined by &gt;3 unformed bowel movements (or &gt;200 mL of unformed stool for subjects having rectal collection devices) in the 24 hours before randomization, and presence of either <span class="Italics">C. difficile</span> toxin A or B in the stool within 48 hours of randomization. Enrolled patients had either no prior CDAD history or only one prior CDAD episode in the past three months. Subjects with life-threatening/fulminant <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, peritoneal signs, significant <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, or toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span> were excluded.</p>
<p>The demographic profile and baseline CDAD characteristics of enrolled subjects were similar in the two trials. Patients had a median age of 64 years, were mainly white (90%), female (58%), and inpatients (63%). The median number of bowel movements per day was 6, and 37% of subjects had severe CDAD (defined as 10 or more unformed bowel movements per day or WBC ≥15000/mm<span class="Sup">3</span>). <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> alone was reported in 45% of patients and 84% of subjects had no prior CDAD episode.</p>
<p>The primary efficacy endpoint was the clinical response rate at the end of treatment, based upon improvement in <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or other symptoms such that, in the investigator's judgment, further CDAD treatment was not needed. An additional efficacy endpoint was sustained clinical response 25 days after the end of treatment. Sustained response was evaluated only for patients who were clinical successes at the end of treatment. Sustained response was defined as clinical response at the end of treatment, and survival without proven or suspected CDAD recurrence through 25 days beyond the end of treatment.</p>
<p>The results for clinical response at the end of treatment in both trials, shown in Table 5, indicate that DIFICID is non-inferior to vancomycin based on the 95% confidence interval (CI) lower limit being greater than the non-inferiority margin of -10%.</p>
<p>The results for sustained clinical response at the end of the follow-up period, also shown in Table 5, indicate that DIFICID is superior to vancomycin on this endpoint. Since clinical success at the end of treatment and mortality rates were similar across treatment arms (approximately 6% in each group), differences in sustained clinical response were due to lower rates of proven or suspected CDAD during the follow-up period in DIFICID patients.</p>
<table width="80%">
<caption><span>Table 5. Clinical Response Rates at End-of-Treatment and Sustained Response at 25 days Post-Treatment</span></caption>
<col align="center" width="10%">
<col align="center" width="13%">
<col align="center" width="16%">
<col align="center" width="16%">
<col align="center" width="13%">
<col align="center" width="16%">
<col align="center" width="16%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Confidence interval (CI) was derived using Wilson's score method. Approximately 5%-9% of the data in each trial and treatment arm were missing sustained response information and were imputed using multiple imputation method.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="3"><span class="Bold">Clinical Response at End of Treatment</span></td>
<td class="Botrule Lrule Rrule" align="center" colspan="3"><span class="Bold">Sustained Response at 25 days Post Treatment</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">DIFICID</span><br><span class="Bold">% (N)</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">Vancomycin</span><br><span class="Bold">% (N)</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">Difference</span><br><span class="Bold">(95% CI)<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></span>
</td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">DIFICID</span><br><span class="Bold">% (N)</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">Vancomycin</span><br><span class="Bold">% (N)</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">Difference</span><br><span class="Bold">(95% CI)*</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">Trial 1</span></td>
<td class="Botrule Lrule Rrule" align="center">88%<br>(N=289)</td>
<td class="Botrule Lrule Rrule" align="center">86%<br>(N=307)</td>
<td class="Botrule Lrule Rrule" align="center">2.6%<br>(-2.9%, 8.0%)</td>
<td class="Botrule Lrule Rrule" align="center">70%<br>(N=289)</td>
<td class="Botrule Lrule Rrule" align="center">57%<br>(N=307)</td>
<td class="Botrule Lrule Rrule" align="center">12.7%<br>(4.4%, 20.9%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">Trial 2</span></td>
<td class="Botrule Lrule Rrule" align="center">88% <br>(N=253)</td>
<td class="Botrule Lrule Rrule" align="center">87%<br>(N=256)</td>
<td class="Botrule Lrule Rrule" align="center">1.0%<br>(-4.8%, 6.8%)</td>
<td class="Botrule Lrule Rrule" align="center">72%<br>(N=253)</td>
<td class="Botrule Lrule Rrule" align="center">57%<br>(N=256)</td>
<td class="Botrule Lrule Rrule" align="center">14.6%<br>(5.8%, 23.3%)</td>
</tr>
</tbody>
</table>
<p>Restriction Endonuclease Analysis (REA) was used to identify <span class="Italics">C. difficile</span> baseline isolates in the BI group, isolates associated with increasing rates and severity of CDAD in the US in the years prior to the clinical trials. Similar rates of clinical response at the end of treatment and proven or suspected CDAD during the follow-up period were seen in fidaxomicin-treated and vancomycin-treated patients infected with a BI isolate. However, DIFICID did not demonstrate superiority in sustained clinical response when compared with vancomycin (Table 6).</p>
<table width="80%">
<caption><span>Table 6. Sustained Clinical Response at 25 Days after Treatment by C. difficile REA Group at Baseline</span></caption>
<col align="left" width="30%">
<col align="center" width="22%">
<col align="center" width="22%">
<col align="center" width="26%">
<tfoot><tr class="First Last"><td align="left" colspan="4">* Interaction test between the effect on sustained response rate and BI versus non-BI isolates using logistic regression (p-values: trial 1: 0.009; trial 2: 0.29). Approximately 25% of the mITT population were missing data for REA group. Confidence intervals (CI) were derived using Wilson's score method.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule" align="left" colspan="4"><span class="Bold">Trial 1</span></td></tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="left">
<span class="Bold">Initial </span><span class="Bold Italics">C. difficile</span><span class="Bold"> Group</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">DIFICID</span><br><span class="Bold">n/N (%)</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">Vancomycin</span><br><span class="Bold">n/N (%)</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">Difference</span><br><span class="Bold">(95% CI)*</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="Bold">BI Isolates</span></td>
<td class="Botrule Lrule Rrule" align="center">44/76 (58%)</td>
<td class="Botrule Lrule Rrule" align="center">52/82 (63%)</td>
<td class="Botrule Lrule Rrule" align="center">-5.5% (-20.3%, 9.5%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="Bold">Non-BI Isolates</span></td>
<td class="Botrule Lrule Rrule" align="center">105/126 (83%)</td>
<td class="Botrule Lrule Rrule" align="center">87/131 (66%)</td>
<td class="Botrule Lrule Rrule" align="center">16.9% (6.3%, 27.0%)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="4"><span class="Bold">Trial 2</span></td></tr>
<tr valign="top">
<td class="Botrule Lrule Rrule" align="left">
<span class="Bold">Initial </span><span class="Bold Italics">C. difficile</span><span class="Bold"> Group</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">DIFICID</span><br><span class="Bold">n/N (%)</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">Vancomycin</span><br><span class="Bold">n/N (%)</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">Difference</span><br><span class="Bold">(95% CI)*</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="Bold">BI Isolates</span></td>
<td class="Botrule Lrule Rrule" align="center">42/65 (65%)</td>
<td class="Botrule Lrule Rrule" align="center">31/60 (52%)</td>
<td class="Botrule Lrule Rrule" align="center">12.9% (-4.2%, 29.2%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left"><span class="Bold">Non-BI Isolates</span></td>
<td class="Botrule Lrule Rrule" align="center">109/131 (83%)</td>
<td class="Botrule Lrule Rrule" align="center">77/121 (64%)</td>
<td class="Botrule Lrule Rrule" align="center">19.6% (8.7%, 30.0%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="splSectionPLRReferences"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol class="Arabic"><li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard - 7<span class="Sup">th</span> edition.</span> CLSI document M11-A7. CLSI, 940 West Valley Rd., Suite 1400, Wayne, PA 19087-1898, 2007.</li></ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionPLRHowSupplied"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection7"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">DIFICID<span class="Sup">®</span> tablets are white to off-white film-coated, oblong tablets containing 200 mg of fidaxomicin; each tablet is debossed with "FDX" on one side and "200" on the other side.</p>
<p>DIFICID tablets are supplied as bottles of 20 tablets (NDC 52015-080-01).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection8"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage</h2>
<p class="First">Storage: 20 °-25°C (68 °-77°F); excursions permitted to 15° - 30°C (59° - 86°F).</p>
<p>See USP controlled room temperature.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPLRPatientInfo"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection9"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Administration with Food</h2>
<p class="First">Patients should be informed that DIFICID tablets may be taken with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection10"></a><a name="section-16.2"></a><p></p>
<h2>17.2 Antibacterial Resistance</h2>
<p class="First">Patients should be counseled that antibacterial drugs, including DIFICID, should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span>. Patients should be counseled that DIFICID only treats <span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and should not be used to treat any other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. When DIFICID tablets are prescribed, patients should be told that, although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by DIFICID or other antibacterial drugs in the future.</p>
<p><br><span class="Bold">Distributed by:</span><br>Cubist Pharmaceuticals U.S.<br>Lexington, MA 02421 USA<br>Made in Canada.</p>
<p>DIFICID<span class="Sup">®</span> is a registered trademark of Cubist Pharmaceuticals in the United States.</p>
<p>Product protected by US Patent Nos. 7,378,508; 7,507,564; 7,863,249; and 7,906,489</p>
<p>©2014 Cubist Pharmaceuticals. All rights reserved.</p>
<p>0500004-00</p>
<p>2000006523</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 200 mg Tablet Carton</h1>
<p class="First"><span class="Bold">NDC 52015-080-01<br>20 tablets</span></p>
<p><span class="Italics"><span class="Bold">DIFICID<span class="Sup">®</span></span><br>(fidaxomicin) tablets</span></p>
<p><span class="Bold">200 </span> mg per tablet</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">CUBIST</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 200 mg Tablet Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd966338-c820-4270-b704-09ef75fa3ceb&amp;name=dificid-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DIFICID 		
					</strong><br><span class="contentTableReg">fidaxomicin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52015-080</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FIDAXOMICIN</strong> (FIDAXOMICIN) </td>
<td class="formItem">FIDAXOMICIN</td>
<td class="formItem">200 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYLATED HYDROXYTOLUENE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LECITHIN, SOYBEAN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (oblong) </td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">FDX;200</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52015-080-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA201699</td>
<td class="formItem">05/27/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cubist Pharmaceuticals U.S.
							(808394928)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Biocon Limited</td>
<td class="formItem"></td>
<td class="formItem">650501997</td>
<td class="formItem">api manufacture(52015-080)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Biocon Limited</td>
<td class="formItem"></td>
<td class="formItem">650173537</td>
<td class="formItem">api manufacture(52015-080)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Inc</td>
<td class="formItem"></td>
<td class="formItem">240769596</td>
<td class="formItem">analysis(52015-080), manufacture(52015-080)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>dfc4d700-ac72-4585-bfc4-dff74ccc3e18</div>
<div>Set id: dd966338-c820-4270-b704-09ef75fa3ceb</div>
<div>Version: 4</div>
<div>Effective Time: 20140529</div>
</div>
</div> <div class="DistributorName">Cubist Pharmaceuticals U.S.</div></p>
</body></html>
